Skip to main content
SpringerLink
Log in

Clinical Magnetic Resonance Neuroimaging in Mild Cognitive Impairment and Alzheimer Disease

  • Chapter
Psychiatry and Neuroscience Update

Abstract

Aging is the primary risk factor for dementia. With increasing life expectancy and aging populations worldwide, dementia is becoming one of the most significant public health problems of the century. The most common pathology underlying dementia in older adults is Alzheimer disease (AD). The use of biomarkers is growing in the early detection of AD. Although some biomarkers such as medial temporal lobe volumetry, amyloid positron emission tomography (PET), and Aβ42 in cerebrospinal fluid are being widely used, there is no clear consensus about the best biomarker to be used in each phase of the disease. Magnetic resonance spectroscopy (MRS) of the brain is a less known biomarker, but has proved useful according to cross-sectional and longitudinal studies. This technique measures metabolite levels that reflect the degree of pathology in the brain. Proton MRS may provide a window into the biochemical changes associated with the loss of neuronal integrity and other neurodegenerative pathology that involve the brain before the manifestations of cognitive impairment in patients who are at risk for AD. Longitudinal studies have demonstrated good correlation between N-acetylaspartate levels and progression of AD, even in spite of treatment with cholinesterase inhibitors. Other emergent neuroimaging modalities such as PET with novel ligands, arterial spin labeling magnetic resonance imaging (MRI) and noncerebral blood flow single-photon emission computerized tomography are only discussed briefly. Other structural and functional MRI (diffusion-tensor) have also added interesting contribution to the understanding of the pathophysiology of AD.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch Neurol. 1999;56:303–8.

    Article  CAS  PubMed  Google Scholar 

  2. Turner RS. Biomarkers of Alzheimer’s disease and mild cognitive impairment: are we there yet? Exp Neurol. 2003;183:7–10.

    Article  PubMed  Google Scholar 

  3. Savva GM, Wharton SB, Ince PG, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. N Engl J Med. 2009;360:2302–9.

    Article  CAS  PubMed  Google Scholar 

  4. Sitoh YY, Kanagasabai K, Earnest A, Sahadevan S. Evaluation of dementia: the case for neuroimaging all mild to moderate cases. Ann Acad Med Singapore. 2006;35:383–9.

    PubMed  Google Scholar 

  5. Sauter R, Schneider K, Wicklow K, Kolem H. Localized1H MRS of the human brain: single voxel versus CSI techniques. J Magn Reson Imaging. 1991;1:241.

    Article  Google Scholar 

  6. Hsu YY, Chen MC, Lim KE, Chang C. Reproducibility of hippocampal single-voxel proton MR spectroscopy and chemical shift imaging. Am J Roentgenol. 2001;176:529–36.

    Article  CAS  Google Scholar 

  7. Maheshwari SR, Fatterpekar GM, Castillo M, Mukherji SK. Proton MR spectroscopy of the brain. Semin Ultrasound CT MR. 2000;21:434–51.

    Article  CAS  PubMed  Google Scholar 

  8. Fayed N, Olmos S, Morales H, Modrego PJ. Physical basis of magnetic resonance spectroscopy and its application to central nervous system diseases. Am J Appl Sci. 2006;3:1836–45.

    Article  CAS  Google Scholar 

  9. Hancu I, Zimmerman EA, Sailasuta N, Hurd RE. 1H MR spectroscopy using TE averaged PRESS: a more sensitive technique to detect neurodegeneration associated with Alzheimer’s disease. Magn Reson Med. 2005;53:777–82.

    Article  CAS  PubMed  Google Scholar 

  10. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9.

    Article  CAS  PubMed  Google Scholar 

  11. Rapoport SI. Hydroge n magnetic resonance spectroscopy in Alzheimer’s disease. Lancet Neurol. 2002;1:82.

    Article  PubMed  Google Scholar 

  12. Modrego PJ. Predictors of conversion to dementia of probable Alzheimer type in patients with mild cognitive impairment. Curr Alzheimer Res. 2006;3:161–70.

    Article  CAS  PubMed  Google Scholar 

  13. Valenzuela MJ, Sachdev P. Magnetic resonance spectroscopy in AD. Neurology. 2001;56:592–8.

    Article  CAS  PubMed  Google Scholar 

  14. Siger M, Schuff N, Zhu X, Miller BL, Weiner MW. Regional myo-inositol concentration in mild cognitive impairment using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2009;23:57–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging. 2011;32:802–10.

    Article  CAS  PubMed  Google Scholar 

  16. Fayed N, Modrego PJ, Rojas-Salinas G, Aguilar K. Brain glutamate levels are decreased in Alzheimer’s disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen. 2011;26:450–6.

    Article  PubMed  Google Scholar 

  17. Kantarci K, Petersen RC, Boeve BF, Knopman DS, Tang-Wai DF, O’Brien PC, Weigand SD, Edland SD, Smith GE, Ivnik RJ, Ferman TJ, Tangalos EG, Jack Jr CR. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Parnetti L, Lowenthal DT, Presciutti O, Pelliccioli GP, Palumbo R, Gobbi G, Chiarini P, Palumbo B, Tarducci R, Senin U. 1 H-MRS, MRI-based hippocampal volumetry, and 99mTc-HMPAO-SPECT in normal aging, age-associated memory impairment, and probable Alzheimer’s disease. J Am Geriatr Soc. 1996;44:133–8.

    Article  CAS  PubMed  Google Scholar 

  19. Kantarci K, Xu Y, Shiung MM, O’Brien PC, Cha RH, Smith GE. Comparative diagnostic utility of different MR modalities in mild cognitive impairment and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2002;14:198–207.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer’s disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry. 2005;162:667–75.

    Article  PubMed  Google Scholar 

  21. Fayed N, Davila J, Oliveros A, Castillo J, Medrano JJ. Utility of different MR modalities in mild cognitive impairment and its use as a predictor of conversion to probable dementia. Acad Radiol. 2008;15:1089–98.

    Article  PubMed  Google Scholar 

  22. Fayed N, Dávila J, Oliveros A, Medrano J, Castillo J. Correlation of findings in advanced MR techniques with global severity scales in patients with some grade of cognitive impairment. Neurol Res. 2010;32:157–65.

    Article  CAS  PubMed  Google Scholar 

  23. Modrego PJ, Fayed N, Sarasa M. Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study. BMJ Open. 2011;1:e000007.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Kantarci K, Weigand SD, Przybelski SA, Shiung MM, Whitwell JL, Negash S, Knopman DS, Boeve BF, O’Brien PC, Petersen RC, Jack Jr CR. Risk of dementia in MCI. Combined effect of cerebrovascular disease, volumetric MRI, and H MRS. Neurology. 2009;72:1519–25.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Kantarci K, Knopman DS, Dickson DW, Parisi JE, Whitwell JL, Weigand SD, Josephs KA, Boeve BF, Petersen RC, Jack Jr CR. Alzheimer disease: postmortem neuropathologic correlates of antemortem 1-H MR Spectroscopy metabolite measurements. Radiology. 2008;248:210–20.

    Article  PubMed Central  PubMed  Google Scholar 

  26. Godbolt AK, Waldman AD, MacManus DG, Schott JM, Frost C, Cipolotti L. MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology. 2006;66:718–22.

    Article  CAS  PubMed  Google Scholar 

  27. Kantarci K, Weigand SD, Petersen RC, Boeve BF, Knopman DS, Gunter J. Longitudinal 1H MRS changes in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2007;28:1330–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Ernst T, Chang L, Melchor R, Mehringer CM. Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR spectroscopy. Radiology. 1997;203:829–36.

    Article  CAS  PubMed  Google Scholar 

  29. MacKay S, Ezekiel F, Di Sclafani V, Meyerhoff DJ, Gerson J, Norman D. Alzheimer disease and subcortical ischemic vascular dementia: evaluation by combining MR imaging segmentation and H-1 MR spectroscopic imaging. Radiology. 1996;198:537–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. MacKay S, Meyerhoff DJ, Constans JM, Norman D, Fein G, Weiner MW. Regional gray and white matter metabolite differences in subjects with AD, with subcortical ischemic vascular dementia, and elderly controls with 1H magnetic resonance spectroscopic imaging. Arch Neurol. 1996;53:167–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. Firbank MJ, Harrison RM, O’Brien JT. A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson’s disease. Dement Geriatr Cogn Disord. 2002;14:64–76.

    Article  CAS  PubMed  Google Scholar 

  32. Fayed N, Modrego PJ, Medrano J. Comparative test-retest reliability of metabolite values assessed with magnetic resonance spectroscopy of the brain. The LCModel versus the manufacturer software. Neurol Res. 2009;31:472–7.

    Article  PubMed  Google Scholar 

  33. Satlin A, Bodick N, Offen WW, Renshaw PF. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer’s disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am J Psychiatry. 1997;154:1459–61.

    Article  CAS  PubMed  Google Scholar 

  34. Frederick B, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. Am J Geriatr Psychiatry. 2002;10:81–8.

    Article  PubMed  Google Scholar 

  35. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology. 2003;226:315–36.

    Article  PubMed  Google Scholar 

  36. Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu X, Perdomo C, Ieni JR, Rogers S. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer disease. Am J Psychiatry. 2003;160:2003–11.

    Article  PubMed  Google Scholar 

  37. Modrego PJ, Pina MA, Fayed N, Díaz M. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer’s disease: a nonrandomised controlled trial with magnetic resonance spectroscopy. CNS Drugs. 2006;20:867–87.

    Article  CAS  PubMed  Google Scholar 

  38. Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M. Memantine versus donepezil in mild to moderate Alzheimer’s disease: a randomized trial with magnetic resonance spectroscopy. Eur J Neurol. 2010;17:405–12.

    Article  CAS  PubMed  Google Scholar 

  39. Schott JM, Frost C, Macmanus DG, Ibrahim F, Waldman AD, Fox ND. Short echo time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal multiple time point study. Brain. 2010;133:3315–22.

    Article  PubMed Central  PubMed  Google Scholar 

  40. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:104–10.

    Article  CAS  PubMed  Google Scholar 

  41. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci. 2008;31:317–76.

    Article  Google Scholar 

  42. Basser PJ, Pierpaoli C. Microstructural and physiological features of tissues elucidated by quantitative-diffusion-tensor MRI. J Magn Reson B. 1996;111:209–19.

    Article  CAS  PubMed  Google Scholar 

  43. Ramani A, Jensen JH, Helpern JA. Quantitative MR imaging in Alzheimer disease. Radiology. 2006;241:26–44.

    Article  PubMed  Google Scholar 

  44. Huang J, Friedland RP, Auchus AP. Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol. 2007;28:1943–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Zhang Y, Schuff N, Jahng G, Bayne W, Mori S, Schad L, Mueller S, Du T, Kramer J, Yaffe K, Chui H, Jagust W, Miller B, Weiner M. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology. 2007;68:13–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  46. Sexton CE, Kalu UG, Filippini N, Mackay CE, Ebmeier KP. A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2011;32:2322.

    Article  PubMed  Google Scholar 

  47. Bendlin BB, Ries ML, Canu E, Sodhi A, Lazar M, Alexander AL, Carlsson CM, Sager MA, Asthana S, Johnson SC. White matter is altered with parental family history of Alzheimer’s disease. Alzheimers Dement. 2010;6:394–403.

    Article  PubMed Central  PubMed  Google Scholar 

  48. Gold BT, Johnson NF, Powell DK, Smith CD. White matter integrity and vulnerability to Alzheimer’s disease: preliminary findings and future directions. Biochim Biophys Act. 1822;2012:416–22.

    Google Scholar 

  49. Grambaite R, Reinvang I, Selnes P, Fjell AM, Walhovd KB, Stenset V, Fladby T. Pre-dementia memory impairment is associated with white matter tract affection. J Int Neuropsychol Soc. 2011;17:143–53.

    Article  PubMed  Google Scholar 

  50. Bozoki AC, Korolev IO, Davis NC, Hoisington LA, Berger KL. Disruption of limbic white matter pathways in mild cognitive impairment and Alzheimer’s disease: a DTI/FDG-PET study. Hum Brain Mapp. 2012;33:1792–802.

    Article  PubMed  Google Scholar 

  51. Wang PN, Chou KH, Lirng JF, Lin KN, Chen WT, Lin CP. Multiple diffusivities define white matter degeneration in amnestic mild cognitive impairment and Alzheimer’s disease. J Alzheimers Dis. 2012;30:423–37.

    PubMed  Google Scholar 

  52. Douaud G, Jbabdi S, Behrens TE, Menke RA, Gass A, Monsch AU, Rao A, Whitcher B, Kindlmann G, Matthews PM, Smith S. DTI measures in crossingfibre areas: increased diffusion anisotropy reveals early white matter alteration in MCI and mild Alzheimer’s disease. Neuroimage. 2011;55:880–90.

    Article  PubMed  Google Scholar 

  53. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O’Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer’s disease. Brain. 2011;134(Pt 4):1089–100.

    Article  PubMed  Google Scholar 

  54. Belliveau JW, Rosen BR, Kantor HL, Rzedzian RR, Kennedy DN, McKinstry RC, Vevea JM, Cohen MS, Pykett IL, Brady TJ. Functional cerebral imaging by susceptibility-contrast NMR. Magn Reson Med. 1990;14:538–46.

    Article  CAS  PubMed  Google Scholar 

  55. Fayed-Miguel N, Castillo-Blandino J, Medrano-Lin J. Perfusion by magnetic resonance imaging: its physical foundations and clinical application. Rev Neurol. 2010;50:23–32.

    PubMed  Google Scholar 

  56. Johnson NA, Jahng GH, Weiner MW, Miller BL, Chui HC, Jagust WJ, Gorno-Tempini ML, Schuff N. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin labeling MR imaging: initial experience. Radiology. 2005;234:851–9.

    Article  PubMed Central  PubMed  Google Scholar 

  57. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer’s disease by spin-labeled magnetic resonance imaging. Ann Neurol. 2000;47:93–100.

    Article  CAS  PubMed  Google Scholar 

  58. Chao LL, Shannon W, Buckley ST, Kornak J, Schuff N, Madison C, Yaffe K, Miller B, Kramer J, Weiner M. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord. 2010;24:19–27.

    Article  PubMed Central  PubMed  Google Scholar 

  59. Boccardi M, Ganzola R, Bocchetta M, Pievani M, Redolfi A, Bartzokis G, Camicioli R, Csernansky JG, de Leon MJ, de Toledo-Morrell L, Killiany RJ, Lehéricy S, Pantel J, Pruessner JC, Soininen H, Watson C, Duchesne S, Jack Jr CR, Frisoni GB. Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI Harmonized Protocol. J Alzheimers Dis. 2011;26:61–75.

    PubMed  Google Scholar 

  60. Barnes J, Bartlett J, Van de Pol L, Loy C, Scahill R, Frost C, Thompson P, Fox NC. A meta-analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol Aging. 2009;30:1711–23.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Lepore N, Brun C, Chou YY, Chiang MC, Dutton R, Hayashi K, Luders E, Lopez O, Aizenstein H, Toga A, Becker J, Thompson P. Generalized tensor-based morphometry of HIV/AIDS using multivariate statistics on deformation tensors. IEEE Trans Med Imaging. 2008;27:129–41.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Li X, Coyle D, Maguire L, Watson DR, McGinnity TM. Gray matter concentration and effective connectivity changes in Alzheimer’s disease: a longitudinal structural MRI study. Neuroradiology. 2011;53:733–48.

    Article  PubMed  Google Scholar 

  63. Golby A, Silverberg G, Race E, Gabrieli S, O’Shea J, Knierim K, Stebbins G, Gabrieli J. Memory encoding in Alzheimer’s disease: an fMRI study of explicit and implicit memory. Brain. 2005;128:773–87.

    Article  PubMed  Google Scholar 

  64. Miettinen PS, Pihlajamäki M, Jauhiainen AM, Niskanen E, Hänninen T, Vanninen R, Soininen H. Structure and function of medial temporal and posteromedial cortices in early Alzheimer’s disease. Eur J Neurosci. 2011;34:320–30.

    Article  PubMed  Google Scholar 

  65. Solé-Padullés C, Bartrés-Faz D, Junqué C, Vendrell P, Rami L, Clemente IC, Bosch B, Villar A, Bargalló N, Jurado MA, Barrios M, Molinuevo JL. Brain structure and function related to cognitive reserve variables in normal aging, mild cognitive impairment and Alzheimer’s disease. Neurobiol Aging. 2009;30:1114–24.

    Article  PubMed  Google Scholar 

  66. Dickerson BC, Salat DH, Bates JF, Atiya M, Killiany RJ, Greve DN. Medial temporal lobe function and structure in mild cognitive impairment. Ann Neurol. 2004;56:27–35.

    Article  PubMed Central  PubMed  Google Scholar 

  67. Wang Z, Yan C, Zhao C, Qi Z, Zhou W, Lu J, He Y, Li K. Spatial patterns of intrinsic brain activity in mild cognitive impairment and Alzheimer’s disease: a resting-state functional MRI study. Hum Brain Mapp. 2011;32:1720–40.

    Article  PubMed  Google Scholar 

  68. Ioannidis JP. Excess significance bias in the literature on brain volume abnormalities. Arch Gen Psychiatry. 2011;68:773–80.

    Article  PubMed  Google Scholar 

  69. Fayed N, Modrego PJ, Salinas GR, Gazulla J. Magnetic resonance imaging based clinical research in Alzheimer’s disease. J Alzheimers Dis. 2012;31 Suppl 3:S5–18.

    PubMed  Google Scholar 

  70. Mandal PK, Tripathi M, Sugunan S. Brain oxidative stress: detection and mapping of anti-oxidant marker ‘Glutathione’ in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy. Biochem Biophys Res Commun. 2012;417:43–8.

    Article  CAS  PubMed  Google Scholar 

  71. Jagust W, Gitcho A, Sun F, Kuczynski B, Mungas D, Haan M. Brain imaging evidence of preclinical Alzheimer’s disease in normal aging. Ann Neurol. 2006;59:673–81.

    Article  PubMed  Google Scholar 

  72. Dickerson BC, Stoub TR, Shah RC, Sperling RA, Killiany RJ, Albert MS, Hyman BT, Blacker D, Detoledo-Morrell L. Alzheimer-signature MRI biomarker predicts AD dementia in cognitively normal adults. Neurology. 2011;76:1395–402.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  73. den Heijer T, Geerlings MI, Hoebeek FE, Hofman A, Koudstaal PJ, Breteler MMB. Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. Arch Gen Psychiatry. 2006;63:57–62.

    Article  Google Scholar 

  74. Wirth M, Villeneuve S, Haase CM, Madison CM, Oh H, Landau SM, Rabinovici GD, Jagust WJ. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 2013. doi:10.1001/jamaneurol.2013.4013.

    PubMed  Google Scholar 

  75. Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A. Alzheimer’s disease neuroimaging initiative. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer’s dementia. Neurobiol Aging. 2002;35:143–51.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neuroradiology, Quirón Hospital, Zaragoza, Spain

    Nicolás Fayed

  2. Department of Psychiatry, Miguel Servet Hospital, University of Zaragoza, Zaragoza, Spain

    Javier Garcia-Campayo

  3. Preventative Activities and Health Promotion Network (REDIAPP), Zaragoza, Spain

    Laura Viguera

Authors
  1. Nicolás Fayed
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Garcia-Campayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura Viguera
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolás Fayed .

Editor information

Editors and Affiliations

  1. Guaymallen Mendoza, Argentina

    Pascual Ángel Gargiulo

  2. Member of the Council of the Institute of Neurobiology (Buenos Aires); Member of the Board of Certification, National Academy of Medicine (Argentina), Psychiatrist by University Complutense of Madrid and University of Buenos Aires; Former Director of National Institute of Mental Health (Argentina), Cuyo, Buenos Aires, Argentina

    Humberto Luis Mesones Arroyo

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Fayed, N., Garcia-Campayo, J., Viguera, L. (2015). Clinical Magnetic Resonance Neuroimaging in Mild Cognitive Impairment and Alzheimer Disease. In: Gargiulo, P., Arroyo, H. (eds) Psychiatry and Neuroscience Update. Springer, Cham. https://doi.org/10.1007/978-3-319-17103-6_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17103-6_28

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17102-9

  • Online ISBN: 978-3-319-17103-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation